ClinVar Miner

Submissions for variant NM_000314.7(PTEN):c.210-1G>A (rs1114167621)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000491234 SCV000579959 pathogenic Hereditary cancer-predisposing syndrome 2019-03-09 criteria provided, single submitter clinical testing The c.210-1G>A intronic pathogenic mutation, results from a G to A one nucleotide upstream from coding exon 4 of the PTEN gene. This mutation has been reported in multiple individuals with classic Cowden syndrome and Cowden Syndrome-like features (Celebi JT et al. Hum. Genet. 2000 Sep; 107(3):234-8; Ngeow J et al. J. Clin. Endocrinol. Metab. 2011 Dec; 96(12):E2063-71; Chen HJ et al. Hum. Mutat. 2017 10;38(10):1372-1377; Heald B et al. Gastroenterology 2010 Dec;139(6):1927-33; Mester J et al. Urology 2012 May;79(5):1187.e1-7; Nizialek EA et al. Eur. J. Hum. Genet. 2015 Nov;23(11):1538-43). In addition, mRNA studies performed have shown that this mutation results in out-of-frame skipping of exon 4 and a premature termination codon in exon 5 (Celebi JT et al. Hum. Genet. 2000 Sep;107(3):234-8; Chen HJ et al. Hum. Mutat. 2017 10;38(10):1372-1377). <span style="background-color:initial">In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000507780 SCV000602115 pathogenic not provided 2016-06-10 criteria provided, single submitter clinical testing
GeneDx RCV000507780 SCV000616839 pathogenic not provided 2018-05-04 criteria provided, single submitter clinical testing This variant is denoted PTEN c.210-1G>A or IVS3-1G>A and consists of a G>A nucleotide substitution at the -1 position of intron 3 of the PTEN gene. This variant destroys a canonical splice acceptor site and has been demonstrated by RT-PCR studies to cause abnormal gene splicing, leading to skipping of exon 4 and subsequent nonsense-mediated mRNA decay (Celebi 2000, Agrawal 2005, Chen 2017). This variant has been reported in several individuals with features of PTEN Hamartoma Tumor syndrome, with at least one de novo observation (Celebi 2000, Mester 2012, Ngeow 2012, Iskandarli 2016, Chen 2017). Based on the current evidence, we consider this variant to be pathogenic.
Invitae RCV000645050 SCV000766790 pathogenic PTEN hamartoma tumor syndrome 2019-08-21 criteria provided, single submitter clinical testing This sequence change affects an acceptor splice site in intron 3 of the PTEN gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been reported in an individual affected with Cowden syndrome (PMID: 11071384), and in a cohort of individuals with thyroid cancer and Cowden or Cowden-Like syndrome (PMID: 21956414). ClinVar contains an entry for this variant (Variation ID: 427616). Experimental studies have shown that this variant disrupts mRNA splicing (PMID: 11071384). Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PTEN are known to be pathogenic (PMID: 9467011, 21194675). For these reasons, this variant has been classified as Pathogenic.
Cancer Genomic Medicine Translational Research Lab,Cleveland Clinic Genomic Medicine Institute RCV000515846 SCV000579228 pathogenic Cowden syndrome 1 2017-05-26 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.